Abstract
Previous work from our group showed that genetic immunization of mice with HIV-1 tat genes (tat22 and tat22/37), encoding Tat proteins mutated in the transactivation domain and lacking Tat-transactivating activity, evoke an immune response to wild-type Tat, both humoral and cellular. In the present work we report that the mutated Tat proteins localize within the cells, are released and taken up by the cells in a fashion similar to wild-type Tat. Moreover, the exogenous mutated Tat proteins interfere with the transactivating function of extracellular wild-type Tat. These results support the notion that tat22 and tat22/37 genes may represent good candidates for the development of an anti-HIV-1 vaccine, especially for HIV-1 infected patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS Vaccines / genetics*
-
AIDS Vaccines / isolation & purification
-
Animals
-
Cell Line
-
Gene Products, tat / genetics*
-
Gene Products, tat / immunology
-
Gene Products, tat / isolation & purification
-
Genes, Viral
-
HIV Infections / immunology
-
HIV Infections / prevention & control
-
HIV Infections / therapy
-
HIV-1 / genetics*
-
Humans
-
Mice
-
Mutation*
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / immunology
-
Recombinant Fusion Proteins / isolation & purification
-
Transcriptional Activation
-
Transfection
-
tat Gene Products, Human Immunodeficiency Virus
Substances
-
AIDS Vaccines
-
Gene Products, tat
-
Recombinant Fusion Proteins
-
tat Gene Products, Human Immunodeficiency Virus